source
- Australian clinical trials attract more U.S. sponsors amid regulatory uncertaintyCROs are reporting faster startup timelines, predictable regulation, and tax incentives as reasons for increasing interest in conducting clinical trials in Australia. State-level incentives in Que…
- Corxel opts for SPAC merger to take oral obesity drug public on NasdaqCorxel Pharmaceuticals, an obesity-focused biotech, said it will merge with Amanat Acquisition in the first half of next year to become a publicly traded company on Nasdaq. The company’s CFO noted…